Clinical and microbiological characteristics of thoracic empyema: retrospective analysis in a tertiary care centre
DOI:
https://doi.org/10.18203/2349-3933.ijam20174166Keywords:
Clinical, College, Empyema, Medical, MicrobiologyAbstract
Background: Clinicians should monitor characteristics of empyema to improve clinical decision making. The objective of this study was to evaluate the clinical and microbiological characteristics of patients of thoracic empyema in a tertiary hospital.
Methods: From 01 January 2016 to 31 December 2016, 110 patients with thoracic empyema were treated. An analysis of organisms cultured from empyema fluid and their antibiotic sensitivity patterns was done. The organism isolated from the pleural fluid, were classified into four groups: gram positive; gram negative; acid fast bacilli (AFB) and fungal. Observational, retrospective chart review design study conducted in Department of Pulmonary Medicine, Era’s Lucknow Medical College and Hospital, a tertiary level health care centre.
Results: Cultures yielded 136 isolates from 96 patients (90.66%) whereas samples from 14 patients (09.34%) were sterile. The isolates were classified as gram positive (20), gram negative (110), AFB (4), fungal (2) and sterile (14). Gram negative bacteria were the most common organism. The prevalence of multi drug resistant Pseudomonas aeruginosa was 12%. 50% of all Staphylococcus aureus were Methicillin resistant.
Conclusions: There is high prevalence of gram-negative bacilli and the high rates of isolation of multi drug resistant Pseudomonas aeruginosa and Methicillin resistant Staphylococus aureus in empyema. This indicates a need for judicial use of antibiotics at the referring centres and more aggressive antibiotic therapy at the referral centres. The practise of empirical broad spectrum antibiotic treatment of empyema must be reviewed.
References
Fraser RS, Muller NL, Colman N, Pare PD. Pleural Effusion. In. Fraser and Pare’s Diagnosis of Diseases of the Chest, 4th ed., Volume IV. Philadelphia, W.B. Saunders Company; 1999:2741-2747.
Light RW. Pleural diseases. 3rd edn. Baltimore, Williams and Wilkins; 1995. In Hamm H, Light RW. Parapneumonic effusion and empyema. Eur Respir J. 1997;10:1150-6.
Chen KY, Hsueh P, Liaw Y, Yang P, Luh K. A 10-year experience with bacteriology of acute thoracic empyema. Chest. 2000;117:1685-9.
Mancini P, Mazzei L, Zarzana A, Biagioli D, Sposato B, Croce GF. Post-tuberculosis chronic empyema of the "forty years after". Eur Rev Med Pharmacol Sci. 1998;2:25-9.
Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. Am J Med. 2006:119:877-83.
Finley C, Clifton J, Fitzgerald JM. Empyema: an increasing concern in Canada. Can Respir J. 2008;15:85-9.
Brims FJH, Lansley SM, Waterer GW, Lee YCG. Empyema thoracic: new insights into an old disease. Eur Respir Rev. 2010;19:117:220-8.
Lardinois D, Gock M, Pezzetta E, Buchli C, Rousson V, Furrer M, et al. Delayed referral and gram-negative organisms increase the conversion thoracotomy rate in patients undergoing video assisted thoracoscopic surgery for empyema. Ann Thorac Surg. 2005;79:1851-6.
Liang SJ, Chen W, Lin Y, Tu C, Chen H, Tsai Y, et al. CommunityAcquired Thoracic Empyema in Young Adults. Southern Med J. 2007;100:1075-80.
Rao S. Tuberculosis and patient gender: An analysis and its implications in tuberculosis control. Lung India. 2009;26:46-7.
Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I. et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Gregorakos L Crit Care. 2003;7:78-83.
Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJ. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med. 2006;174:817-23.
Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis. 2001;32:146-55.
